Attorney Fred J. Fleming of Fleming, Greenwald, & Associates, represents claimants in social security disability and SSI hearings for over 40 years. In addition to his work as an attorney, Fred J. Fleming is also a lecturer at the National Multiple Sclerosis Society (NMSS), an organization working toward freeing the world of multiple sclerosis.
In January 2021, a study published on the NMSS site reported that patients that adhered to disease-modifying therapies, such as injectable and oral medications, reduced the incidence of relapse and deterioration of condition. The study followed 14,000 people who were patients at medical centers for 15 years to see the effects of on-going treatment. The information gathered is stored in the MSBase Registry, an online registry for physicians who study multiple sclerosis and other neurological conditions.
The study compared patients who remained with disease-modifying treatments versus those who did not. Adhering to treatments resulted in a 40 percent reduction in relapses and reduced the need for any aid for walking by 67 percent.
The article also acknowledges that the observational study in no way takes the place of a randomized clinical trial, but it does provide insight into the role of disease-modifying treatments in managing the condition. For more information regarding the specifics of the study, the actual article was published online on December 28, 2020, in the journal Neurology.
In January 2021, a study published on the NMSS site reported that patients that adhered to disease-modifying therapies, such as injectable and oral medications, reduced the incidence of relapse and deterioration of condition. The study followed 14,000 people who were patients at medical centers for 15 years to see the effects of on-going treatment. The information gathered is stored in the MSBase Registry, an online registry for physicians who study multiple sclerosis and other neurological conditions.
The study compared patients who remained with disease-modifying treatments versus those who did not. Adhering to treatments resulted in a 40 percent reduction in relapses and reduced the need for any aid for walking by 67 percent.
The article also acknowledges that the observational study in no way takes the place of a randomized clinical trial, but it does provide insight into the role of disease-modifying treatments in managing the condition. For more information regarding the specifics of the study, the actual article was published online on December 28, 2020, in the journal Neurology.
